A PROSPECTIVE ANALYSIS OF SURGICAL OUTCOMES AND PATIENTS SATISFACTION RATE AFTER AMS SPECTRA PENILE PROSTHESIS IMPLANTATION

Objective: From the beginning of 2010, the AMS Spectra penile prosthesis can be used to treat erectile dysfunction (ED). The Spectra is a non-infl atable concealable penile prosthesis composed of a pair of cylinders, each with a center malleable section of articulating polymer and metal segments. The aim of this paper is to evaluate the outcomes, the patient and their partner satisfaction on the AMS Spectra penile prosthesis implantation. Methods: 22 patients, unresponsive or non satisfi ed with i-pde 5 oral therapy or prostaglandin intracavernous injection, underwent to a Spectra penile prosthesis implantation. No major intraoperative neither postoperative complications were assessed. The preoperative ED was rated by the IIEF questionnaire. The etiology of ED was Peyronie’s disease (PD) in 17 patients (77%), post-radical prostatectomy (RRP) in 3 patients (14%) and PD+RRP in 2 more patients (9%). To evaluate the satisfaction score, patients and partners were evaluated by IIEF and EDITS questionnaires by a telephonic interview at 3, 6 and 12 months after penile surgery. Results: The study demonstrates that 86,4% of patients are longterm satisfi ed by the AMS Spectra penile prosthesis. The pre-operative average IIEF score was 28,5 [13–39]. Postoperative IIEF rates were respectively 47,7 [43–53], 51,8 [48–58], 53,9 [50–58] at 3, 6, 12 months. The patient average EDITS score was respectively 39,5 [31– 48]; 43,4 [36–50]; 45,2 [38–50] at 3, 6, 12 months. The increasing between preoperative and postoperative IIEF and EDITS parameters resulted statistically signifi cant. Partners EDITS medium scores were respectively 14,9 [10–20], 16,7 [11–24], 17,8 [11–24] at 3, 6, 12 months. Conclusion: AMS Spectra is a reliable device to treat the erectile dysfunction.This prosthesis should be considered, in selected patients, as an affective solution to treat severe ED.